NK Cell Therapy Pipeline Outlook, Clinical Trials, FDA Approvals, and Companies 2024 (Updated)

DelveInsight's, "NK Cell Therapy Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the NK Cell Therapy Pipeline Report

* DelveInsight's NK Cell Therapy pipeline report depicts a robust space with 100+ active players working to develop 185+ pipeline therapies for NK Cell Therapy treatment.
* The leading companies working in the NK Cell Therapy Market include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
* Promising NK Cell Therapy Pipeline Therapies in the various stages of development include Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.
* April 2024:- Phase I/II Study of Brentuximab Vedotin and Methotrexate/ L-asparaginase/ Dexamethasone (B-MAD) Chemotherapy in Patients With Newly-diagnosed Extranodal NK/ T-cell Lymphoma. The Thai Lymphoma Study Group- Study Title: Phase I/II study of brentuximab vedotin and methotrexate/ L-asparaginase/ dexamethasone (B-MAD) chemotherapy in patients with newly-diagnosed Extranodal NK/T-cell Lymphoma
* April 2024:- Antengene Corporation- This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which will be chosen by investigators (ICE [ifosfamide+carboplatin+etoposide] or GEMOX [gemcitabine+oxaliplatin] or Tislelizumab), after treatments of 2 to 6 cycles transferring to ATG-010 monotherapy maintenance treatment, to evaluate the safety, tolerability, and primary efficacy of ATG-010 in R/R PTCL and NK/T-cell lymphoma patients.
* April 2024:- Coeptis Therapeutics- A Phase 1 Study of DVX201, an Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19. This study is being done to determine the highest tolerated dose of an investigational cell therapy called DVX201 in patients hospitalized with COVID-19. DVX201 is an allogeneic NK (natural killer) cell therapy. NK cells are a normal part of your immune system that have the ability to identify and kill cells in the body that are infected by viruses such as COVID-19. There is evidence that both NK cell exhaustion and low numbers of NK cell in the blood occur in COVID-19 patients, and this may contribute to worsening of the infection. Therefore, infusion of healthy functional NK cells (like DVX201) may help overcome COVID-19 infection and prevent progression of the disease. This study is being done to look at the safety and tolerability of DVX201 in patients with COVID-19 and to gather information on how COVID-19 responds to treatment with DVX201.
* April 2024:- Vaxcell Bio Co. Ltd- A Phase 2a Study Using Natural Killer (NK) Cell Therapy Combined With Hepatic Artery Infusion Chemotherapy (HAIC) in Patients With Locally Advanced Hepatocellular Carcinoma. This Phase 2a trial will evaluate the safety and efficacy of NK cell therapy combined with the hepatic artery infusion chemotherapy (HAIC) in patients with intermediate and/or locally advanced hepatocellular carcinoma (HCC).

Request a sample and discover the recent advances in NK Cell Therapy Treatment Drugs @ NK Cell Therapy Infection Pipeline Outlook Report [https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

In the NK Cell Therapy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

NK Cell Therapy Overview

Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm.

Find out more about NK Cell Therapy Treatment Landscape @ Drugs for NK Cell Therapy Treatment [https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

NK Cell Therapy Emerging Drugs Profile

* NKTR-214: Nektar therapeutics
* Monalizumab: Innate Pharma
* Bemarituzumab: Five Prime Therapeutics
* ALT 803: ImmunityBio
* CellProtect: XNK Therapeutics
* K-NK002: Kiadis Pharma
* NK-92: ImmunityBio
* WU-NK-101: Wugen
* Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
* ALECSAT: CytoVac

NK Cell Therapy Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The NK Cell Therapy companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.

DelveInsight's NK Cell Therapy pipeline report covers around 185+ products under different phases of clinical development like

* Late-stage products (Phase III and
* Mid-stage products (Phase II and
* Early-stage products (Phase I/II and Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

NK Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravaginal
* Oral
* Parenteral
* Subcutaneous
* Topical.
* Molecule Type

NK Cell Therapy Pipeline Products have been categorized under various Molecule types such as

* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type

Learn more about the emerging NK Cell Therapy Pipeline Therapies @ NK Cell Therapy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the NK Cell Therapy Pipeline Report

* Coverage- Global
* NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
* NK Cell Therapy Pipeline Therapies- Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.

Dive deep into rich insights for new drugs for NK Cell Therapy treatment, Visit @ NK Cell Therapy Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Natural Killer (NK) cell therapy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* NKTR-214: Nektar therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CellProtect: XNK Therapeutics
* Drug profiles in the detailed report.....
* Early stage products (Phase I/II)
* Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Natural Killer (NK) cell therapy Key Companies
* Natural Killer (NK) cell therapy Key Products
* Natural Killer (NK) cell therapy- Unmet Needs
* Natural Killer (NK) cell therapy- Market Drivers and Barriers
* Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
* Natural Killer (NK) cell therapy Analyst Views
* Natural Killer (NK) cell therapy Key Companies
* Appendix

For further information on the NK Cell Therapy pipeline therapeutics, reach out @ NK Cell Therapy Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nk-cell-therapy-pipeline-outlook-clinical-trials-fda-approvals-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.